The Technical Analyst
Scopus Biopharma Inc. [SCPS]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Scopus Biopharma Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $0.0016
America/New_York / 18 apr 2024 @ 13:25
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 0.0673 mill |
| EPS: | -0.310 |
| P/E: | -0.0100 |
| Earnings Date: | May 12, 2023 |
| SharesOutstanding: | 42.08 mill |
| Avg Daily Volume: | 0.0013 mill |
| RATING 2024-04-18 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 1/22 | 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0100 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE -0.0100 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0006 - 0.0026 ( +/- 62.50%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2021-11-23 | Greenspan Ira Scott | Sell | 3 000 000 | W Warrants |
| 2021-11-23 | Lamstein Joshua R | Sell | 3 000 000 | W Warrants |
| 2021-06-01 | Hopper Paul | Buy | 6 333 | Common Stock |
| 2020-12-15 | Hopper Paul | Buy | 0 | Common Stock |
| 2020-12-15 | Hopper Paul | Sell | 0 | Common Stock |
| INSIDER POWER |
|---|
| 0.00 |
| Last 55 transactions |
| Buy: 2 180 518 | Sell: 6 965 870 |
Forecast:
15:05 - $0.0020
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $0.0016 (0.00% ) |
| Volume | 0.0000 mill |
| Avg. Vol. | 0.0013 mill |
| % of Avg. Vol | 2.16 % |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SCPS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
SCPS
Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. The company lead development programs are immuno-oncology gene therapy for the treatment of various cancers. It offers Duet Platform, a CpG signal transducer and activator of transcription 3 (STAT3) inhibitors; and MRI-1867, rationally designed, orally available, dual-action, hybrid, and small molecule that is an inverse agonist of the endocannabinoid system/cannabinoid receptor 1, as well as an inhibitor of inducible nitric oxide synthase. Scopus BioPharma Inc. has strategic partnerships with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem for its lead development and other programs. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.
Last 10 Buy Signals
Latest Press Releases
2023-11-07 09:15:00 - Press Release
Scopus Biopharma's Subsidiary — Duet Biotherapeutics — Presents Compelling New Data For A Novel Treatment For Malignant Glioma At 38th Annual Meeting Of The Society For Immunotherapy Of Cancer
Duet-102 in combination with pd-1 blockade demonstrates significant anti-tumor activity in models of malignant glioma
2023-11-02 09:15:00 - Press Release
Scopus Biopharma's Subsidiary — Duet Biotherapeutics — To Present At The 38th Annual Meeting Of The Society For Immunotherapy Of Cancer
New york, nov. 02, 2023 (globe newswire) -- scopus biopharma inc. (otcqb: “scps ”), a biotechnology company developing transformational therapeutics for serious diseases with significant unmet medical need, and its subsidiary, duet biotherapeutics inc., which is developing novel immunotherapies to overcome treatment-resistant cancers, today announced that marcin kortylewski, ph.d., co-founder and senior scientific advisor of duet and professor of immuno-oncology at city of hope, will be presenting at the 38th annual meeting of the society for immunotherapy of cancer (“sitc”). sitc is being held from november 3-5, 2023, in san diego, california.
2022-03-22 20:30:00 - Press Release
Scopus Biopharma's Subsidiary — Duet Biotherapeutics — To Present At The 3rd Annual Sting & Tlr-targeting Therapies Summit
Alan horsager, ph.d., president and chief executive officer of duet, to present on tlr9 activation and stat3 inhibition: a bifunctional approach to immuno-oncology
2021-10-08 17:30:00 - Press Release
Scopus Biopharma Announces Adjournment Of Annual Meeting Of Stockholders
New york, oct. 08, 2021 (globe newswire) -- scopus biopharma inc. (nasdaq: “scps”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today announced that, on october 8, 2021, its 2021 annual meeting of stockholders (the “annual meeting”) was adjourned to 1:00 p.m., eastern time, on friday, november 5, 2021, without any business being conducted, pursuant to a stipulation and court order approved by the delaware court of chancery between scopus and morris c. laster, m.d. in connection with dr. laster's pending claims against scopus in the delaware court of chancery. notwithstanding the stipulation and court order requiring dr...
2021-10-05 08:45:00 - Press Release
Scopus Biopharma To Present At The Ld Micro Main Event
Scopus to present on the recent launch of duet therapeutics, its wholly-owned subsidiary focused on immuno-oncology
Latest News
2023-11-02 09:15:00 - GlobeNewsWire
Scopus BioPharma's Subsidiary — Duet BioTherapeutics — to Present at the 38th Annual Meeting of the Society for Immunotherapy of Cancer
NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (OTCQB: “SCPS ”), a biotechnology company developing transformational therapeutics for serious diseases with significant unmet medical need, and its subsidiary, Duet BioTherapeutics Inc., which is developing novel immunotherapies to overcome treatment-resistant cancers, today announced that Marcin Kortylewski, Ph.D., Co-Founder and Senior Scientific Advisor of Duet and Professor of Immuno-Oncology at City of Hope, will be presenting at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (“SITC”). SITC is being held from November 3-5, 2023, in San Diego, California.
2022-03-22 20:30:00 - GlobeNewsWire
Scopus BioPharma's Subsidiary — Duet BioTherapeutics — to Present at the 3rd Annual STING & TLR-Targeting Therapies Summit
Alan Horsager, Ph.D., President and Chief Executive Officer of Duet, to Present on TLR9 Activation and STAT3 Inhibition: A Bifunctional Approach to Immuno-Oncology
2021-10-08 17:30:00 - GlobeNewsWire
Scopus BioPharma Announces Adjournment of Annual Meeting of Stockholders
NEW YORK, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today announced that, on October 8, 2021, its 2021 Annual Meeting of Stockholders (the “Annual Meeting”) was adjourned to 1:00 p.m., Eastern time, on Friday, November 5, 2021, without any business being conducted, pursuant to a Stipulation and Court Order approved by the Delaware Court of Chancery between Scopus and Morris C. Laster, M.D. in connection with Dr. Laster's pending claims against Scopus in the Delaware Court of Chancery. Notwithstanding the Stipulation and Court Order requiring Dr...
2021-10-05 08:45:00 - GlobeNewsWire
Scopus BioPharma to Present at the LD Micro Main Event
Scopus to present on the recent launch of Duet Therapeutics, its wholly-owned subsidiary focused on immuno-oncology
2021-10-01 16:30:00 - GlobeNewsWire
Scopus BioPharma Retaining Counsel to Investigate Unusual Market Activity
NEW YORK, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company, announced today that it is retaining Boies Schiller Flexner LLP to conduct a market manipulation investigation.
2021-10-01 07:00:00 - GlobeNewsWire
Scopus BioPharma to Present at MicroCap Rodeo's Fall Harvest Best Ideas Conference
Scopus to present on the recent launch of Duet Therapeutics, its wholly-owned subsidiary focused on immuno-oncology
2021-09-29 08:30:00 - GlobeNewsWire
Scopus BioPharma's Subsidiary — Duet Therapeutics — Announces Release of Preclinical Data Being Presented at 17th Annual Meeting of the Oligonucleotide Therapeutics Society
Data from two different studies benchmark Duet's proprietary bifunctional oligonucleotides against immune checkpoint inhibitors (“Checkpoint Inhibitors”) in lymphoma and prostate tumor models in mice
2021-09-28 09:15:00 - GlobeNewsWire
Scopus BioPharma's Subsidiary Duet Therapeutics Set to Release Scientific Data During the 17th Annual Meeting of the Oligonucleotide Therapeutics Society
Duet releases video depicting mechanism of action for its proprietary CpG-STAT3 inhibitors to coincide with Duet presentations at OTS Meeting Duet releases video depicting mechanism of action for its proprietary CpG-STAT3 inhibitors to coincide with Duet presentations at OTS Meeting
2021-09-28 06:30:00 - GlobeNewsWire
Scopus BioPharma's Subsidiary — Duet Therapeutics — Set to Release Scientific Data During the 17th Annual Meeting of the Oligonucleotide Therapeutics Society
Duet releases video depicting mechanism of action for its proprietary CpG-STAT3 inhibitors to coincide with Duet presentations at OTS Meeting Duet releases video depicting mechanism of action for its proprietary CpG-STAT3 inhibitors to coincide with Duet presentations at OTS Meeting
2021-09-28 06:00:00 - GlobeNewsWire
Scopus BioPharma to Adjourn 2021 Annual Meeting of Stockholders
NEW YORK, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, announced today that, pursuant to a stipulation with Morris C. Laster, M.D. in connection with pending claims brought by Dr. Laster in the Delaware Court of Chancery, the company intends to convene, and then immediately adjourn, the company's scheduled October 8, 2021 Annual Meeting of Stockholders (the “Annual Meeting”) such that the Annual Meeting will be held and the vote on the items of business to be considered at the Annual Meeting will be taken no earlier than 14 days after a decision on the merits or a final settlement between the parties...